P2, N=30, Not yet recruiting, Sirnaomics

In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials.

P=N/A, N=165, Not yet recruiting, Beijing Tiantan Hospital

P2, N=287, Completed, Washington University School of Medicine | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Jul 2025 --> Jun 2026

This exploratory pharmacodynamic biomarker analysis identifies three 3-cytokine panels associated with prognostic risk stratification in metronomic chemotherapy for metastatic gastrointestinal cancer. As this single-arm trial cannot distinguish prognostic from predictive value, findings are hypothesis-generating. Prospective external validation is required before clinical translation, and exploration in combination with immune checkpoint inhibitors is warranted.

P4, N=120, Not yet recruiting, University of Miami | Initiation date: Jun 2026 --> Jan 2027

P=N/A, N=174, Not yet recruiting, Te Whatu Ora Waitemata

P1/2, N=78, Completed, Heron Therapeutics | Phase classification: P1b/2 --> P1/2

Leveraging clinical feasible RNA-seq and TMB analysis, our model exhibits robust predictive efficacy of ICB response in multiple cancers, enabling subtype-tailored therapeutic combinations to improve immunotherapy response.

The system is constructed using celecoxib (CXB)-loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles and subsequently camouflaging them with mesenchymal stem cell membranes with high CXCR4 expression...This dual modulation of the chemokine network significantly improves the therapeutic efficacy of CAR-T cells against solid tumors. Our approach represents a promising strategy for advancing CAR-T cell therapy toward clinical applications for soild tumors.

P3, N=209, Completed, Heron Therapeutics | Phase classification: P3b --> P3 | N=115 --> 209

By integrating genetic causal inference, in vitro experiments, and network pharmacology, our study systematically reveals that celecoxib may exert therapeutic effects by targeting against cervical cancer by targeting NEU1 and modulating CD25 on CD45RA+ CD4+ non-regulatory T cell-related immune pathways. This finding highlights both the novelty and the translational potential of this approach.